Chiltern Partners With Karolinska Development

LONDON and WILMINGTON, N.C., Feb. 12, 2014 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), proudly announces our partnership with Karolinska Development in Sweden, a life science investment company listed on NASDAQ OMX Stockholm (ticker: KDEV). Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations.

"We are extremely pleased to be selected as the partner CRO for Karolinska Development after an extensive CRO selection process in 2012. We were selected based on our compatibility with Karolinska Development's specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project" stated Dr Jim Esinhart, CEO of Chiltern.   

Aize Smink, Chiltern's Chief Operating Officer, commented "We are honored and proud to be partnering with Karolinska Development, a world class organization committed to life science innovations and bringing novel therapies to market. A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.

Company profile

About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery.

Further information is available at: www.chiltern.com.

About Karolinska Development:
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 35 projects, of which 16 are in clinical development.

Further information is available at: www.karolinskadevelopment.com.

SOURCE Chiltern

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED